I-Mab Forms Two Novel Drug Discovery Collaborations

I-Mab, a Shanghai biopharma, formed two new collaborations, one with Complix of the EU and the other with Shanghai Affinity Biopharma, to discover differentiated drug candidates. Complix's Cell Penetrating Alphabodies (CPAB) platform discovers candidates for intractable intracellular drug targets and masked antibodies for targeted tumor-site activation. Affinity focuses on finding candidates that become active only in the tumor micro environment. I-Mab said the new partners will be paid milestones, though it did not release further details of the agreements. More details.... Stock Symbol: (NSDQ: IMAB) Share this with colleagues: // //